Insmed Inc INSM:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 03/05/21 EST
38.13UNCH (UNCH)
Volume
7,498
Close
38.13quote price arrow up+0.84 (+2.25%)
Volume
1,439,724
52 week range
12.09 - 45.44

...

Loading . . .

KEY STATS

  • Open37.26
  • Day High38.63
  • Day Low36.20
  • Prev Close37.29
  • 52 Week High45.44
  • 52 Week High Date02/09/21
  • 52 Week Low12.09
  • 52 Week Low Date03/17/20
  • Market Cap3.929B
  • Shares Out103.04M
  • 10 Day Average Volume1.02M
  • Dividend-
  • Dividend Yield-
  • Beta2.34
  • 1 Year % Change65.06

RATIOS/PROFITABILITY

  • EPS (TTM)-3.00
  • P/E (TTM)-12.69
  • Fwd P/E (NTM)-11.82
  • EBITDA (MRQ)-250.004M
  • ROE (MRQ)-109.42%
  • Revenue (MRQ)164.41M
  • Gross Margin (MRQ)75.75%
  • Net Margin (MRQ)-178.87%
  • Debt To Equity (MRQ)134.88%

EVENTS

  • Earnings Date04/28/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Insmed Inc News

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Insmed Incorporated is a global biopharmaceutical company. The Company’s product ARIKAYCE (amikacin liposome inhalation suspension) is developed for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The Company's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic...
William Lewis
Chairman
Roger Adsett
Chief Operating Officer
Sara Bonstein
Chief Financial Officer
John Goll
Chief Accounting Officer
Address
700 US Highway 202/206
Bridgewater, NJ
08807-1704
United States